SCM
AIMT

Silvant Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Silvant Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,288
Closed -$172K – 340
2020
Q2 		$172K Buy
10,288
+2,669
+35% +$45.3K 0.03% 181
2020
Q1 		$110K Hold
7,619
– – 0.02% 192
2019
Q4 		$255K Buy
+7,619
New +$213K 0.05% 166

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Silvant Capital Management's AIMT Position: Q3 2020 in Review

Silvant Capital Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 10,288 shares — an estimated $172K sold.

Silvant Capital Management first reported a position in AIMT in Q4 2019 and held it in 3 quarters. The position peaked at $255K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Silvant Capital Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Silvant Capital Management sold 10,288 Aimmune Therapeutics shares in Q3 2020, an estimated $172K.
  • Silvant Capital Management first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 3 quarters.
  • Silvant Capital Management's Aimmune Therapeutics position peaked at $255K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Silvant Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.